Eight late-stage pipeline products are expected to launch during the forecast period.
The Parkinson’s disease (PD) market across the seven major markets (7MM) is expected to reach $7b in 2033 at a compound annual growth rate of 7.6%, according to GlobalData.
The sector’s expansion is attributed to the expected launches of eight late-stage pipeline products during the forecast period.
Currently, therapy is focused on symptomatic treatment, according to Christie Wong, Managing Neurology Analyst at GlobalData.
The need for disease-modifying therapies is one of the greatest unmet needs in the PD space,” Wong said.
However, potential challenges include the loss of exclusivity for key branded products, as their patent and data exclusivity periods expire, leading to the entry of cheaper generics into the market.
“Nonetheless, the launches of the pipeline therapies, including symptomatic and disease-modifying therapies, will drive market growth,” Wong added.
7MM- US, France, Germany, Italy, Spain, UK, and Japan
